Liapis Konstantinos, Vrachiolias Georgios, Papadopoulos Vasileios, Kourakli Alexandra, Galanopoulos Athanasios G, Papoutselis Menelaos, Papageorgiou Sotirios G, Diamantopoulos Panagiotis T, Pappa Vassiliki, Viniou Nora-Athina, Vassilakopoulos Theodoros P, Hatzimichael Eleftheria, Bouronikou Eleni, Ximeri Maria, Pontikoglou Charalambos, Panayiotidis Panayiotis, Karakatsanis Stamatis, Vardi Anna, Symeonidis Argiris, Kotsianidis Ioannis
Department of Hematology Democritus University of Thrace Medical School Alexandroupolis Greece.
Department of Internal Medicine University Hospital of Patras Rio Greece.
EJHaem. 2020 Jul 1;1(1):255-261. doi: 10.1002/jha2.30. eCollection 2020 Jul.
Cardiovascular disease (CVD) emerges as a major cause of death in patients with myelodysplastic syndrome (MDS), but predictors of fatal CVD and the effect of MDS-specific treatments on CVD mortality remain largely unknown. In an analysis involving 831 patients with MDS with known causes of death, we noted an independent association of lower risk MDS, age >70 years, pre-existing CVD, and treatment with erythropoiesis-stimulating agents with a higher risk of death from CVD. If externally validated, these simple risk factors could increase clinicians' awareness toward CVD complications and guide early introduction of intensive monitoring and preventive interventions in MDS patients.
心血管疾病（CVD）已成为骨髓增生异常综合征（MDS）患者的主要死因，但致命性CVD的预测因素以及MDS特异性治疗对CVD死亡率的影响仍 largely unknown。在一项涉及831例已知死亡原因的MDS患者的分析中，我们注意到低危MDS、年龄>70岁、既往存在CVD以及使用促红细胞生成素治疗与CVD死亡风险较高存在独立关联。如果能得到外部验证，这些简单的风险因素可提高临床医生对CVD并发症的认识，并指导对MDS患者尽早进行强化监测和预防性干预。
